Rani Therapeutics (RANI) Institutional Ownership → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free RANI Stock Alerts $4.39 -0.14 (-3.09%) (As of 06/7/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Rani Therapeutics (NASDAQ:RANI)CurrentInstitutional OwnershipPercentage30.19%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$283.98KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$113.56K Get RANI Insider Trade Alerts Want to know when executives and insiders are buying or selling Rani Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data RANI Institutional Buying and Selling by Quarter Ad Paradigm PressTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. Rani Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/10/2024 Vanguard Group Inc.685,303$2.13M0.0%+2.5%1.366% 2/14/2024 Alpha Square Group S LLC58,946$196K0.2%-32.2%0.118% 8/10/2023 King Luther Capital Management Corp56,129$231K0.0%N/A0.113% 8/4/2023 Choreo LLC19,813$82K0.0%-20.2%0.040% 5/11/2023Icon Wealth Partners LLC12,757$66K0.0%N/A0.026% 5/11/2023 Alphabet Inc.448,492$2.31M0.1%-12.1%0.908% Get the Latest News and Ratings for RANI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Rani Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/8/2023 Prime Capital Investment Advisors LLC33,502$198K0.0%N/A0.068% 11/18/2022TPB Wealth Advisors48,129$461K0.2%-33.0%0.098% 11/16/2022 Alphabet Inc.714,471$6.85M0.3%N/A1.453% 11/3/2022 Motco48,129$461K0.0%N/A0.098% 10/28/2022 Lafayette Investments Inc.19,893$191K0.1%N/A0.040% 10/17/2022 Canton Hathaway LLC16,200$155K0.1%+88.4%0.033% 10/14/2022 Iowa State Bank18,862$181K0.1%N/A0.038% 8/8/2022 Islay Capital Management LLC9,611$99K0.1%N/A0.020% 8/8/2022Crossvault Capital Management LLC14,285$148K0.1%N/A0.029% 7/29/2022Aspireon Wealth Advisors71,811$742K0.3%N/A0.146% 7/20/2022 Canton Hathaway LLC8,600$89K0.0%N/A0.017% 6/15/2022 Lasry Marc62,828$848K0.4%N/A0.128% 5/17/2022 Lasry Marc62,828$848K0.4%N/A0.128% 5/13/2022 United Services Automobile Association481,300$6.50M0.1%N/A0.979% 2/3/2022 Advisor Group Holdings Inc.21,072$344K0.0%N/A0.043% 1/6/2022 Canton Hathaway LLC5,000$82K0.0%-50.0%0.010% 11/16/2021 Squarepoint Ops LLC50,000$891K0.0%N/A0.102% 11/15/2021 Caas Capital Management LP75,000$1.34M0.0%N/A0.153% 11/10/2021 Goldman Sachs Group Inc.60,649$1.08M0.0%N/A0.124% (Data available from 1/1/2016 forward) RANI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of RANI shares? During the previous two years, 16 institutional investors and hedge funds held shares of Rani Therapeutics. The most heavily invested institutionals were Alphabet Inc. ($2.31M), Vanguard Group Inc. ($2.13M), Lasry Marc ($848K), Aspireon Wealth Advisors ($742K), TPB Wealth Advisors ($461K), Motco ($461K), and King Luther Capital Management Corp ($231K).Learn more on RANI's institutional investors. What percentage of Rani Therapeutics stock is owned by institutional investors? 30.19% of Rani Therapeutics stock is owned by institutional investors. Learn more on RANI's institutional investor holdings. Which institutional investors have been buying Rani Therapeutics stock? Of the 13 institutional investors that purchased Rani Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Alphabet Inc. ($714.47K), Aspireon Wealth Advisors ($71.81K), Lasry Marc ($62.83K), King Luther Capital Management Corp ($56.13K), Motco ($48.13K), Prime Capital Investment Advisors LLC ($33.50K), and Lafayette Investments Inc. ($19.89K). How much institutional buying is happening at Rani Therapeutics? Institutional investors have bought a total of 1,095,434 shares in the last 24 months. This purchase volume represents approximately $10.22M in transactions. Which Rani Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Rani Therapeutics stock in the last 24 months: Alphabet Inc. ($61.64K), Alpha Square Group S LLC ($28K), TPB Wealth Advisors ($23.68K), and Choreo LLC ($5K). How much institutional selling is happening at Rani Therapeutics? Institutional investors have sold a total of 118,318 shares in the last 24 months. This volume of shares sold represents approximately $658.48K in transactions. Related Companies: PASG Major Shareholders GRCL Major Shareholders TYRA Major Shareholders GYRE Major Shareholders ARQT Major Shareholders IRON Major Shareholders SPRY Major Shareholders IMNM Major Shareholders ABVX Major Shareholders CNTA Major Shareholders This page (NASDAQ:RANI) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersMillionaire-Making “Wealth Pattern” Just Repeated on April 22If you think you missed out on the Bitcoin band wagon… You need to watch this immediately.Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rani Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rani Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.